NASH: The Next Untapped Pharma Market Gives Investors Many Options NASH: The Next Untapped Pharma Market Gives Investors Many Options

Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat non-alcoholic steatohepatitis (NASH), a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.Reuters Health Information
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Gastroenterology News Source Type: news